Aerovate Therapeutics, Inc.·4

May 3, 6:00 PM ET

Verwijs Marinus 4

4 · Aerovate Therapeutics, Inc. · Filed May 3, 2024

Insider Transaction Report

Form 4
Period: 2024-05-02
Verwijs Marinus
Senior Vice President, CMC
Transactions
  • Sale

    Common Stock

    2024-05-02$21.02/sh1,981$41,6310 total
Footnotes (3)
  • [F1]The sales reported in this Form 4 were effected pursuant to E*TRADE Securities LLC's Quicksale Trading Plan elected by the reporting person on July 11, 2022.
  • [F2]Includes 1,981 shares purchased under the Issuer's 2021 Employee Stock Purchase Plan on April 30, 2024 in a transaction that is exempt under Rule 16b-3(c) and 16b-3(d).
  • [F3]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.972 to $21.12, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Documents

1 file
  • 4
    form4-05032024_060504.xmlPrimary